Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.

导出 OA

翻译打印收藏纠错

作者： Michael,Heuser ^[1] ; B Douglas,Smith ^[2] ; Walter,Fiedler ^[3] ; Mikkael A,Sekeres ^[4] ; Pau,Montesinos ^[5] ; Brian,Leber ^[6] ; Akil,Merchant ^[7] ; Cristina,Papayannidis ^[8] ; José A,Pérez-Simón ^[9] ; Caroline J,Hoang ^[10] ; Thomas,O'Brien ^[11] ; Weidong Wendy,Ma ^[11] ; Mirjana,Zeremski ^[11] ; Ashleigh,O'Connell ^[11] ; Geoffrey,Chan ^[11] ; Jorge E,Cortes ^[11]

作者单位： Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Heuser.Michael@mh-hannover.de. ^[1] Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. ^[2] Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. ^[3] Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, FL, Miami, USA. ^[4] Hospital Universitari i Politècnic La Fe, Valencia, Spain. ^[5] CIBERONC, Instituto Carlos III, Madrid, Spain. ^[6] Juravinski Hospital at Hamilton Health Sciences, Hamilton, ON, Canada. ^[7] Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ^[8] IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. ^[9] Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IbiS)/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain. ^[10] Pfizer Inc, New York, NY, USA. ^[11] University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[12] Georgia Cancer Center, Augusta, GA, USA. ^[13]

关键词 Acute myeloid leukemia Clinical trial Glasdegib Secondary acute myeloid leukemia